John Corboy
Concepts (393)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 50 | 2025 | 484 | 8.340 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 15 | 2025 | 82 | 3.550 |
Why?
| | Immunologic Factors | 13 | 2025 | 255 | 2.420 |
Why?
| | Neurology | 10 | 2018 | 110 | 2.190 |
Why?
| | Immunosuppressive Agents | 10 | 2024 | 846 | 1.540 |
Why?
| | Neuromyelitis Optica | 4 | 2023 | 137 | 1.090 |
Why?
| | Natalizumab | 11 | 2021 | 41 | 0.900 |
Why?
| | Recurrence | 8 | 2025 | 1134 | 0.850 |
Why?
| | Diagnostic Errors | 2 | 2017 | 175 | 0.680 |
Why?
| | Brain | 16 | 2025 | 2930 | 0.650 |
Why?
| | Internship and Residency | 5 | 2011 | 1255 | 0.620 |
Why?
| | Drug Substitution | 2 | 2019 | 63 | 0.610 |
Why?
| | Fingolimod Hydrochloride | 5 | 2020 | 39 | 0.610 |
Why?
| | Data Collection | 4 | 2011 | 633 | 0.570 |
Why?
| | Rituximab | 4 | 2020 | 209 | 0.570 |
Why?
| | Magnetic Resonance Imaging | 25 | 2026 | 3857 | 0.570 |
Why?
| | Dementia, Vascular | 3 | 2009 | 21 | 0.560 |
Why?
| | Medication Adherence | 2 | 2019 | 512 | 0.520 |
Why?
| | Early Medical Intervention | 1 | 2017 | 61 | 0.500 |
Why?
| | Early Diagnosis | 2 | 2017 | 247 | 0.490 |
Why?
| | Glatiramer Acetate | 6 | 2019 | 18 | 0.480 |
Why?
| | Calcinosis | 2 | 2009 | 233 | 0.470 |
Why?
| | Humans | 88 | 2026 | 144261 | 0.470 |
Why?
| | Drug Monitoring | 1 | 2019 | 389 | 0.460 |
Why?
| | Physicians | 4 | 2016 | 938 | 0.460 |
Why?
| | Postural Balance | 3 | 2018 | 240 | 0.430 |
Why?
| | Antibodies, Monoclonal, Humanized | 8 | 2023 | 985 | 0.400 |
Why?
| | Neuroimaging | 2 | 2026 | 289 | 0.370 |
Why?
| | Fatigue | 3 | 2018 | 361 | 0.360 |
Why?
| | Dimethyl Fumarate | 3 | 2020 | 12 | 0.350 |
Why?
| | Immunoglobulin G | 4 | 2023 | 893 | 0.340 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 3 | 2020 | 28 | 0.310 |
Why?
| | Middle Aged | 39 | 2025 | 35762 | 0.310 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1559 | 0.310 |
Why?
| | Withholding Treatment | 2 | 2021 | 80 | 0.310 |
Why?
| | Adult | 44 | 2026 | 40262 | 0.310 |
Why?
| | Psychiatry | 2 | 2009 | 186 | 0.290 |
Why?
| | Demyelinating Diseases | 4 | 2019 | 84 | 0.280 |
Why?
| | Cysts | 1 | 2009 | 111 | 0.270 |
Why?
| | HIV Long Terminal Repeat | 3 | 2001 | 11 | 0.270 |
Why?
| | Autoantibodies | 3 | 2023 | 1497 | 0.260 |
Why?
| | Education, Medical | 1 | 2011 | 273 | 0.260 |
Why?
| | Lymphopenia | 2 | 2020 | 65 | 0.260 |
Why?
| | Certification | 1 | 2008 | 119 | 0.260 |
Why?
| | Education | 2 | 2007 | 104 | 0.250 |
Why?
| | Central Nervous System Cysts | 1 | 2006 | 13 | 0.250 |
Why?
| | Female | 49 | 2025 | 77976 | 0.250 |
Why?
| | Clinical Trials as Topic | 3 | 2016 | 1050 | 0.240 |
Why?
| | Cerebral Arteries | 1 | 2006 | 58 | 0.240 |
Why?
| | Leukoencephalopathies | 1 | 2026 | 24 | 0.240 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2023 | 53 | 0.240 |
Why?
| | Single-Blind Method | 3 | 2023 | 311 | 0.240 |
Why?
| | Male | 40 | 2025 | 72035 | 0.240 |
Why?
| | Cerebrovascular Disorders | 1 | 2006 | 103 | 0.230 |
Why?
| | DNA, Viral | 2 | 1998 | 358 | 0.230 |
Why?
| | Drug Industry | 2 | 2016 | 48 | 0.230 |
Why?
| | Ethics, Medical | 2 | 2015 | 86 | 0.230 |
Why?
| | Societies, Medical | 4 | 2019 | 886 | 0.220 |
Why?
| | HIV Seropositivity | 2 | 1998 | 118 | 0.220 |
Why?
| | Conflict of Interest | 2 | 2016 | 51 | 0.220 |
Why?
| | Treatment Outcome | 12 | 2023 | 11643 | 0.210 |
Why?
| | White Matter | 1 | 2026 | 151 | 0.210 |
Why?
| | Databases, Factual | 3 | 2016 | 1484 | 0.210 |
Why?
| | Double-Blind Method | 4 | 2023 | 2025 | 0.200 |
Why?
| | AIDS Dementia Complex | 3 | 2001 | 52 | 0.200 |
Why?
| | Microglia | 2 | 2024 | 268 | 0.190 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2023 | 66 | 0.190 |
Why?
| | Heart Aneurysm | 1 | 2002 | 12 | 0.180 |
Why?
| | Quality of Health Care | 2 | 2017 | 688 | 0.170 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2002 | 59 | 0.170 |
Why?
| | B-Lymphocytes | 5 | 2023 | 876 | 0.170 |
Why?
| | Interferon beta-1a | 2 | 2019 | 14 | 0.170 |
Why?
| | Lymphoma | 2 | 2005 | 232 | 0.170 |
Why?
| | Education, Medical, Continuing | 2 | 2015 | 131 | 0.170 |
Why?
| | Mental Disorders | 2 | 2007 | 1138 | 0.160 |
Why?
| | Central Nervous System Neoplasms | 2 | 2005 | 173 | 0.160 |
Why?
| | Agammaglobulinemia | 1 | 2020 | 36 | 0.160 |
Why?
| | Brain Neoplasms | 4 | 2016 | 1318 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 784 | 0.160 |
Why?
| | Serum Sickness | 1 | 2019 | 4 | 0.150 |
Why?
| | Indans | 1 | 2019 | 13 | 0.150 |
Why?
| | Oxadiazoles | 1 | 2019 | 37 | 0.150 |
Why?
| | Neutropenia | 1 | 2020 | 155 | 0.150 |
Why?
| | Disease Progression | 4 | 2021 | 2840 | 0.150 |
Why?
| | Diagnosis, Differential | 4 | 2023 | 1487 | 0.150 |
Why?
| | Referral and Consultation | 1 | 2005 | 847 | 0.140 |
Why?
| | Lymphoma, AIDS-Related | 1 | 1998 | 14 | 0.140 |
Why?
| | Adjuvants, Immunologic | 3 | 2015 | 245 | 0.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 257 | 0.130 |
Why?
| | Salvage Therapy | 1 | 2019 | 162 | 0.130 |
Why?
| | Herpesvirus 8, Human | 1 | 1998 | 68 | 0.130 |
Why?
| | Diffuse Cerebral Sclerosis of Schilder | 1 | 2017 | 4 | 0.130 |
Why?
| | Eye Movements | 1 | 2018 | 92 | 0.130 |
Why?
| | Physician-Patient Relations | 2 | 2016 | 581 | 0.130 |
Why?
| | Educational Measurement | 3 | 2015 | 325 | 0.130 |
Why?
| | Sarcoma, Kaposi | 1 | 1998 | 83 | 0.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2019 | 674 | 0.130 |
Why?
| | Central Nervous System | 2 | 2005 | 281 | 0.130 |
Why?
| | Patient Selection | 2 | 2015 | 719 | 0.130 |
Why?
| | Young Adult | 7 | 2024 | 13990 | 0.130 |
Why?
| | Herpesvirus 4, Human | 1 | 2018 | 176 | 0.130 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 150 | 0.120 |
Why?
| | Nervous System Diseases | 2 | 2024 | 282 | 0.120 |
Why?
| | Neurologists | 1 | 2016 | 22 | 0.120 |
Why?
| | Suicide, Assisted | 1 | 1997 | 31 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2017 | 218 | 0.120 |
Why?
| | Estriol | 1 | 2015 | 6 | 0.120 |
Why?
| | Cost-Benefit Analysis | 2 | 2016 | 623 | 0.120 |
Why?
| | Aged | 9 | 2024 | 25850 | 0.120 |
Why?
| | Corpus Callosum | 2 | 2006 | 72 | 0.110 |
Why?
| | Verbal Learning | 2 | 2013 | 72 | 0.110 |
Why?
| | Dizziness | 2 | 2018 | 101 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1982 | 0.110 |
Why?
| | Retrospective Studies | 10 | 2024 | 17009 | 0.110 |
Why?
| | Follow-Up Studies | 6 | 2020 | 5389 | 0.110 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2006 | 154 | 0.100 |
Why?
| | Trust | 1 | 2016 | 151 | 0.100 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2014 | 59 | 0.100 |
Why?
| | Medication Reconciliation | 1 | 2013 | 31 | 0.100 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2014 | 131 | 0.100 |
Why?
| | CD40 Antigens | 1 | 2014 | 90 | 0.100 |
Why?
| | Insurance, Health | 1 | 2016 | 301 | 0.100 |
Why?
| | JC Virus | 1 | 2013 | 23 | 0.100 |
Why?
| | Exercise Therapy | 1 | 2018 | 467 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 2 | 2006 | 474 | 0.100 |
Why?
| | Stroke | 1 | 2002 | 1254 | 0.100 |
Why?
| | Sensation Disorders | 1 | 2012 | 41 | 0.090 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2012 | 19 | 0.090 |
Why?
| | Population Surveillance | 1 | 2016 | 483 | 0.090 |
Why?
| | Memory Disorders | 1 | 2013 | 193 | 0.090 |
Why?
| | Immunoglobulin Heavy Chains | 3 | 2007 | 85 | 0.090 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2012 | 38 | 0.090 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2012 | 20 | 0.090 |
Why?
| | HIV-1 | 2 | 2001 | 895 | 0.090 |
Why?
| | Optic Nerve | 2 | 2005 | 66 | 0.090 |
Why?
| | T-Lymphocyte Subsets | 1 | 2014 | 415 | 0.090 |
Why?
| | Glioma | 1 | 2016 | 425 | 0.090 |
Why?
| | Gadolinium | 4 | 2018 | 84 | 0.080 |
Why?
| | United States | 8 | 2024 | 15876 | 0.080 |
Why?
| | Academies and Institutes | 1 | 2011 | 60 | 0.080 |
Why?
| | Self-Assessment | 1 | 2011 | 74 | 0.080 |
Why?
| | Nerve Regeneration | 1 | 2010 | 56 | 0.080 |
Why?
| | Learning | 1 | 2015 | 449 | 0.080 |
Why?
| | Fatal Outcome | 3 | 2006 | 307 | 0.080 |
Why?
| | Leukocytosis | 1 | 2010 | 32 | 0.080 |
Why?
| | Diagnostic Tests, Routine | 1 | 2011 | 108 | 0.080 |
Why?
| | Antigens, CD19 | 3 | 2007 | 129 | 0.080 |
Why?
| | Cranial Nerve Neoplasms | 1 | 1989 | 7 | 0.080 |
Why?
| | Hemangioma, Cavernous | 1 | 1989 | 13 | 0.080 |
Why?
| | Optic Chiasm | 1 | 1989 | 18 | 0.080 |
Why?
| | Biomarkers | 3 | 2014 | 4254 | 0.080 |
Why?
| | Central Nervous System Infections | 1 | 2010 | 35 | 0.080 |
Why?
| | Exercise Test | 1 | 2012 | 634 | 0.080 |
Why?
| | Severity of Illness Index | 3 | 2014 | 2917 | 0.080 |
Why?
| | Quality of Life | 3 | 2021 | 3166 | 0.070 |
Why?
| | Disease Management | 1 | 2013 | 643 | 0.070 |
Why?
| | Guidelines as Topic | 1 | 2011 | 267 | 0.070 |
Why?
| | Spinal Cord | 3 | 2023 | 380 | 0.070 |
Why?
| | Neuroprotective Agents | 1 | 2009 | 143 | 0.070 |
Why?
| | Physical Therapy Modalities | 1 | 2011 | 332 | 0.070 |
Why?
| | Hospital-Physician Relations | 1 | 2007 | 3 | 0.070 |
Why?
| | Immunoglobulin Variable Region | 2 | 2004 | 80 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1347 | 0.060 |
Why?
| | Workload | 1 | 2009 | 170 | 0.060 |
Why?
| | Vasculitis, Central Nervous System | 1 | 2006 | 16 | 0.060 |
Why?
| | Headache Disorders | 1 | 2006 | 19 | 0.060 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2006 | 47 | 0.060 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 1129 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1993 | 1128 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 2011 | 1519 | 0.060 |
Why?
| | Methylprednisolone | 1 | 2006 | 64 | 0.060 |
Why?
| | Medical Records | 1 | 2007 | 186 | 0.060 |
Why?
| | Syndrome | 2 | 2023 | 380 | 0.060 |
Why?
| | International Classification of Diseases | 1 | 2007 | 143 | 0.060 |
Why?
| | Antibody Formation | 1 | 2007 | 294 | 0.060 |
Why?
| | Huntington Disease | 1 | 2007 | 61 | 0.060 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2006 | 123 | 0.060 |
Why?
| | Herpes Zoster | 1 | 2010 | 315 | 0.060 |
Why?
| | Contrast Media | 3 | 2018 | 486 | 0.060 |
Why?
| | Intracranial Hemorrhages | 1 | 2006 | 100 | 0.060 |
Why?
| | Aquaporin 4 | 1 | 2006 | 98 | 0.060 |
Why?
| | DNA Mutational Analysis | 1 | 2006 | 405 | 0.060 |
Why?
| | Adolescent | 8 | 2024 | 22281 | 0.060 |
Why?
| | Canada | 2 | 2019 | 428 | 0.060 |
Why?
| | Health Care Surveys | 1 | 2007 | 538 | 0.060 |
Why?
| | Analysis of Variance | 3 | 2015 | 1304 | 0.050 |
Why?
| | Patient Compliance | 1 | 2009 | 585 | 0.050 |
Why?
| | Neurologic Examination | 1 | 2005 | 130 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2009 | 355 | 0.050 |
Why?
| | Teaching | 1 | 2007 | 235 | 0.050 |
Why?
| | Cognition Disorders | 1 | 2009 | 537 | 0.050 |
Why?
| | RNA, Messenger | 1 | 1992 | 2829 | 0.050 |
Why?
| | Surveys and Questionnaires | 4 | 2016 | 6021 | 0.050 |
Why?
| | Program Evaluation | 1 | 2009 | 946 | 0.050 |
Why?
| | Central Nervous System Diseases | 1 | 2005 | 74 | 0.050 |
Why?
| | Colorado | 2 | 2024 | 4562 | 0.050 |
Why?
| | Affect | 1 | 2007 | 318 | 0.050 |
Why?
| | Simvastatin | 1 | 2004 | 59 | 0.050 |
Why?
| | Neutrophils | 1 | 2010 | 1134 | 0.050 |
Why?
| | Proteoglycans | 1 | 2004 | 108 | 0.050 |
Why?
| | Erythrocytes | 1 | 2010 | 757 | 0.050 |
Why?
| | Ophthalmoplegia | 1 | 2003 | 13 | 0.050 |
Why?
| | Prevalence | 2 | 2024 | 2815 | 0.050 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2003 | 53 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2006 | 301 | 0.050 |
Why?
| | B-Lymphocyte Subsets | 1 | 2003 | 80 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2003 | 266 | 0.050 |
Why?
| | Radiography | 1 | 2005 | 842 | 0.050 |
Why?
| | Neurodegenerative Diseases | 1 | 2024 | 150 | 0.050 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 132 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 423 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2005 | 545 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 496 | 0.040 |
Why?
| | Lymphoma, B-Cell | 2 | 2005 | 132 | 0.040 |
Why?
| | Students, Medical | 1 | 2006 | 373 | 0.040 |
Why?
| | Pain | 1 | 2007 | 777 | 0.040 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2024 | 276 | 0.040 |
Why?
| | Anticoagulants | 1 | 2006 | 721 | 0.040 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2001 | 38 | 0.040 |
Why?
| | Molecular Sequence Data | 3 | 2004 | 2929 | 0.040 |
Why?
| | Disability Evaluation | 2 | 2014 | 308 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 356 | 0.040 |
Why?
| | Antibodies, Antinuclear | 1 | 2001 | 62 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2012 | 5813 | 0.040 |
Why?
| | Schools, Medical | 1 | 2002 | 156 | 0.040 |
Why?
| | Peptides | 3 | 2013 | 995 | 0.040 |
Why?
| | Atrophy | 1 | 2021 | 200 | 0.040 |
Why?
| | Dementia | 1 | 2005 | 302 | 0.040 |
Why?
| | Time Factors | 4 | 2018 | 7155 | 0.040 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2001 | 159 | 0.040 |
Why?
| | Mobility Limitation | 1 | 2020 | 66 | 0.040 |
Why?
| | Clinical Competence | 1 | 2008 | 1241 | 0.040 |
Why?
| | Venous Thrombosis | 1 | 2002 | 194 | 0.040 |
Why?
| | Child | 5 | 2016 | 22537 | 0.040 |
Why?
| | Interferon-beta | 2 | 2011 | 92 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2003 | 1126 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 672 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 42 | 0.040 |
Why?
| | Cell Separation | 2 | 2014 | 307 | 0.040 |
Why?
| | Cerebral Infarction | 1 | 1998 | 47 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 87 | 0.040 |
Why?
| | Lipids | 1 | 2023 | 700 | 0.030 |
Why?
| | HIV Seronegativity | 1 | 1998 | 29 | 0.030 |
Why?
| | Genes, myc | 1 | 1998 | 50 | 0.030 |
Why?
| | Base Sequence | 2 | 2001 | 2187 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2019 | 290 | 0.030 |
Why?
| | Astrocytoma | 1 | 1998 | 129 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 2018 | 319 | 0.030 |
Why?
| | Gene Library | 1 | 1997 | 126 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 341 | 0.030 |
Why?
| | Risk Assessment | 1 | 2006 | 3637 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 1998 | 155 | 0.030 |
Why?
| | Managed Care Programs | 1 | 1997 | 136 | 0.030 |
Why?
| | Syndecan-1 | 2 | 2007 | 42 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 778 | 0.030 |
Why?
| | Morals | 1 | 1997 | 80 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2014 | 1172 | 0.030 |
Why?
| | Risk Factors | 3 | 2008 | 10699 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 2008 | 2447 | 0.030 |
Why?
| | Viral Load | 1 | 2018 | 518 | 0.030 |
Why?
| | Mutation | 1 | 2006 | 4085 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 1998 | 1054 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1382 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 1997 | 824 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2016 | 1409 | 0.030 |
Why?
| | Child, Preschool | 3 | 2016 | 11774 | 0.020 |
Why?
| | Incidence | 1 | 2020 | 2870 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2015 | 221 | 0.020 |
Why?
| | Propylene Glycols | 1 | 2013 | 27 | 0.020 |
Why?
| | Ocular Physiological Phenomena | 1 | 1992 | 10 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2014 | 220 | 0.020 |
Why?
| | Patient Care Team | 1 | 2019 | 686 | 0.020 |
Why?
| | Sphingosine | 1 | 2013 | 45 | 0.020 |
Why?
| | beta-Galactosidase | 1 | 1992 | 77 | 0.020 |
Why?
| | Quality-Adjusted Life Years | 1 | 2013 | 117 | 0.020 |
Why?
| | Markov Chains | 1 | 2013 | 126 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1044 | 0.020 |
Why?
| | Leukocyte Count | 1 | 1993 | 316 | 0.020 |
Why?
| | Mice, Inbred DBA | 1 | 1992 | 187 | 0.020 |
Why?
| | Haplotypes | 1 | 2014 | 490 | 0.020 |
Why?
| | Organ Specificity | 1 | 1992 | 312 | 0.020 |
Why?
| | Reference Values | 1 | 2013 | 797 | 0.020 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 169 | 0.020 |
Why?
| | CD3 Complex | 1 | 2012 | 111 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2012 | 117 | 0.020 |
Why?
| | Thymus Gland | 1 | 1992 | 311 | 0.020 |
Why?
| | Mental Recall | 1 | 2013 | 222 | 0.020 |
Why?
| | Intestine, Small | 1 | 1992 | 166 | 0.020 |
Why?
| | Mitoxantrone | 1 | 2011 | 15 | 0.020 |
Why?
| | Hematologic Tests | 1 | 2011 | 21 | 0.020 |
Why?
| | Mice | 2 | 2023 | 18329 | 0.020 |
Why?
| | Muscle Stretching Exercises | 1 | 2011 | 19 | 0.020 |
Why?
| | Animals | 3 | 2023 | 38030 | 0.020 |
Why?
| | Patient Participation | 1 | 2015 | 429 | 0.020 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 96 | 0.020 |
Why?
| | Depression | 2 | 2011 | 1533 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 1992 | 674 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 2004 | 2154 | 0.020 |
Why?
| | Physical Endurance | 1 | 2011 | 278 | 0.020 |
Why?
| | Acyclovir | 1 | 2010 | 96 | 0.020 |
Why?
| | Spinal Cord Neoplasms | 1 | 1989 | 40 | 0.020 |
Why?
| | Cell Count | 1 | 2010 | 320 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2011 | 546 | 0.020 |
Why?
| | History, 19th Century | 1 | 2009 | 61 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2006 | 1705 | 0.020 |
Why?
| | Neoplasms, Multiple Primary | 1 | 1989 | 58 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2016 | 8243 | 0.020 |
Why?
| | Injections | 1 | 2009 | 196 | 0.020 |
Why?
| | History, 21st Century | 1 | 2009 | 219 | 0.020 |
Why?
| | Pilot Projects | 2 | 2004 | 1867 | 0.020 |
Why?
| | Autoimmunity | 1 | 2014 | 924 | 0.020 |
Why?
| | History, 20th Century | 1 | 2009 | 324 | 0.020 |
Why?
| | Electrocardiography | 1 | 2011 | 660 | 0.020 |
Why?
| | Gene Expression | 1 | 1992 | 1487 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 1992 | 2182 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 536 | 0.020 |
Why?
| | Health | 1 | 2007 | 81 | 0.020 |
Why?
| | Memory | 1 | 2009 | 294 | 0.020 |
Why?
| | Association Learning | 1 | 2007 | 71 | 0.020 |
Why?
| | Walking | 1 | 2011 | 545 | 0.020 |
Why?
| | Herpesvirus 3, Human | 1 | 2010 | 336 | 0.020 |
Why?
| | Cerebral Ventricles | 1 | 2006 | 54 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 917 | 0.010 |
Why?
| | Prognosis | 2 | 2006 | 4278 | 0.010 |
Why?
| | Motor Skills | 1 | 2007 | 104 | 0.010 |
Why?
| | Hypothalamus | 1 | 2006 | 153 | 0.010 |
Why?
| | Genetics | 1 | 2005 | 22 | 0.010 |
Why?
| | Phenotype | 1 | 2014 | 3157 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2009 | 582 | 0.010 |
Why?
| | Immunologic Memory | 1 | 2007 | 366 | 0.010 |
Why?
| | Neurosciences | 1 | 2005 | 25 | 0.010 |
Why?
| | Syndecans | 1 | 2004 | 5 | 0.010 |
Why?
| | Social Support | 1 | 2009 | 649 | 0.010 |
Why?
| | Anisotropy | 1 | 2004 | 75 | 0.010 |
Why?
| | Hospitalization | 1 | 2015 | 2424 | 0.010 |
Why?
| | Clinical Protocols | 1 | 2006 | 282 | 0.010 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2006 | 285 | 0.010 |
Why?
| | Immune System | 1 | 2005 | 179 | 0.010 |
Why?
| | Internet | 1 | 2009 | 698 | 0.010 |
Why?
| | Plasma Cells | 1 | 2004 | 75 | 0.010 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 2003 | 4 | 0.010 |
Why?
| | Antiviral Agents | 1 | 2010 | 767 | 0.010 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2003 | 11 | 0.010 |
Why?
| | Meningitis, Viral | 1 | 2003 | 20 | 0.010 |
Why?
| | Infrared Rays | 1 | 2003 | 27 | 0.010 |
Why?
| | Videotape Recording | 1 | 2003 | 37 | 0.010 |
Why?
| | Saccades | 1 | 2003 | 45 | 0.010 |
Why?
| | Antilymphocyte Serum | 1 | 2003 | 61 | 0.010 |
Why?
| | Oligoclonal Bands | 1 | 2003 | 26 | 0.010 |
Why?
| | Antigens, CD34 | 1 | 2003 | 88 | 0.010 |
Why?
| | Clone Cells | 1 | 2003 | 266 | 0.010 |
Why?
| | Whole-Body Irradiation | 1 | 2003 | 76 | 0.010 |
Why?
| | Astrocytes | 1 | 2005 | 222 | 0.010 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2003 | 134 | 0.010 |
Why?
| | Immunoglobulins | 1 | 2003 | 160 | 0.010 |
Why?
| | Observer Variation | 1 | 2003 | 354 | 0.010 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 192 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2006 | 1087 | 0.010 |
Why?
| | ATPases Associated with Diverse Cellular Activities | 1 | 2001 | 9 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 1992 | 5988 | 0.010 |
Why?
| | Age Factors | 1 | 2009 | 3313 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 847 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2730 | 0.010 |
Why?
| | Consensus Sequence | 1 | 2001 | 74 | 0.010 |
Why?
| | Biopsy | 1 | 2005 | 1075 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2009 | 2926 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 981 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2007 | 789 | 0.010 |
Why?
| | Cytomegalovirus Infections | 1 | 2003 | 206 | 0.010 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2001 | 23 | 0.010 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2001 | 56 | 0.010 |
Why?
| | Urinary Tract Infections | 1 | 2003 | 202 | 0.010 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2001 | 94 | 0.010 |
Why?
| | Infant | 1 | 2015 | 10022 | 0.010 |
Why?
| | Cohort Studies | 1 | 2011 | 5935 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2006 | 2111 | 0.010 |
Why?
| | Acute Disease | 1 | 2003 | 1028 | 0.010 |
Why?
| | Research | 1 | 2003 | 428 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2003 | 1264 | 0.010 |
Why?
| | Lung | 1 | 1992 | 4108 | 0.010 |
Why?
| | Arachnoid | 1 | 1998 | 11 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 1983 | 0.010 |
Why?
| | Monocytes | 1 | 2001 | 538 | 0.010 |
Why?
| | Survival Rate | 1 | 2003 | 2088 | 0.010 |
Why?
| | Virus Replication | 1 | 2001 | 529 | 0.010 |
Why?
| | Binding Sites | 1 | 2001 | 1327 | 0.010 |
Why?
| | Models, Biological | 1 | 2005 | 1820 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2004 | 3592 | 0.010 |
Why?
| | Aging | 1 | 2007 | 1964 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2003 | 3403 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2001 | 1495 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2001 | 1497 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2001 | 4146 | 0.010 |
Why?
|
|
Corboy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|